Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1276 participants.

Also called NCT07001800

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 1,276 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07001800
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07001800. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-27 (actual); primary completion 2028-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Acronym
KATALYST-AV
Condition
Moderate Aortic Valve Stenosis
Intervention (Drug)
Ataciguat
Intervention (Drug)
Placebo
Lead sponsor
Kardigan, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07001800
Content hash
e1e8f67173a52139da5cc2dc0b990ad7f1b069ae62eda2c111c389c678834eb7